MondoA is highly overexpressed in acute lymphoblastic leukemia cells and modulates their metabolism, differentiation and survival

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1185-1192

  Wernicke, Caroline M ^a   Richter, Günther H S ^a   Beinvogl, Beate C ^a   Plehm, Stephanie ^a   Schlitter, Anna M ^b   Bandapalli, Obul R ^c,d   Prazeres da Costa, Olivia ^e   Hattenhorst, Uwe E ^f   Volkmer, Ines ^f   Staege, Martin S ^f   Esposito, Irene ^b   Burdach, Stefan ^a   Grunewald, Thomas G P ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Molecular Medicine Partnership Unit (MMPU)   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Clonogenicity; Differentiation; Leukemia; Metabolism; MondoA; MondoB; Survival

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL METABOLISM; CELL SURVIVAL; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; MONDAA GENE; PRIORITY JOURNAL; RNA INTERFERENCE; UPREGULATION;

APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HEP G2 CELLS; HUMANS; JURKAT CELLS; MICROARRAY ANALYSIS; NEOPLASM INVASIVENESS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84864022473     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.05.009     Document Type: Article

References (47)

1. Eden T. Aetiology of childhood leukaemia. Cancer Treat Rev 2010, 36:286-297.
2. Bourquin J.P., Izraeli S. Where can biology of childhood ALL be attacked by new compounds?. Cancer Treat Rev 2010, 36:298-306.
3. Pui C.H., Carroll W.L., Meshinchi S., Arceci R.J. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011, 29:551-565.
4. Grunewald T.G.P., Greulich N., Kontny U., Frühwald M.C., Rutkowski S., Kordes U., et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012, 244:124-131.
5. Richter G., Hattenhorst U.E., Roessler S., Staege M.S., Hansen G., Burdach S. Transcriptome analysis of pediatric cALL versus normal fetal B cells reveals a novel signature of the malignant phenotype. Blood 2005, 106:167B-168B.
6. Billin A.N., Eilers A.L., Coulter K.L., Logan J.S., Ayer D.E. MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network. Mol Cell Biol 2000, 20:8845-8854.
7. Iizuka K., Bruick R.K., Liang G., Horton J.D., Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A 2004, 101:7281-7286.
8. Ishii S., Iizuka K., Miller B.C., Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A 2004, 101:15597-15602.
9. Tong X., Zhao F., Mancuso A., Gruber J.J., Thompson C.B. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci U S A 2009, 106:21660-21665.
10. Ma L., Tsatsos N.G., Towle H.C. Direct role of ChREBP. Mlx in regulating hepatic glucose-responsive genes. J Biol Chem 2005, 280:12019-12027.
11. McFerrin L.G., Atchley W.R. A novel N-terminal domain may dictate the glucose response of mondo proteins. PLoS One 2012, 7:e34803.
12. Billin A.N., Ayer D.E. The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism. Curr Top Microbiol Immunol 2006, 302:255-278.
13. Sans C.L., Satterwhite D.J., Stoltzman C.A., Breen K.T., Ayer D.E. MondoA-Mlx heterodimers are candidate sensors of cellular energy status: mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol 2006, 26:4863-4871.
14. Stoltzman C.A., Peterson C.W., Breen K.T., Muoio D.M., Billin A.N., Ayer D.E. Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc Natl Acad Sci U S A 2008, 105:6912-6917.
15. Kaadige M.R., Elgort M.G., Ayer D.E. Coordination of glucose and glutamine utilization by an expanded Myc network. Transcr 2010, 1:36-40.
16. Sloan E.J., Ayer D.E. Myc, mondo, and metabolism. Genes Cancer 2010, 1:587-596.
17. Beillard E., Pallisgaard N., van der Velden V.H., Bi W., Dee R., van der Schoot E., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486.
18. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
19. Sturn A., Quackenbush J., Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002, 18:207-208.
20. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121.
21. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
22. Grunewald T.G., Diebold I., Esposito I., Plehm S., Hauer K., Thiel U., et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res 2012, 10:52-65.
23. Ge X., Yamamoto S., Tsutsumi S., Midorikawa Y., Ihara S., Wang S.M., et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005, 86:127-141.
24. Balgobind B.V., Van den Heuvel-Eibrink M.M., De Menezes R.X., Reinhardt D., Hollink I.H., Arentsen-Peters S.T., et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011, 96:221-230.
25. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004, 101:9309-9314.
26. Roth R.B., Hevezi P., Lee J., Willhite D., Lechner S.M., Foster A.C., et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 2006, 7:67-80.
27. Andersson A., Ritz C., Lindgren D., Eden P., Lassen C., Heldrup J., et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007, 21:1198-1203.
28. Haferlach T., Kohlmann A., Wieczorek L., Basso G., Kronnie G.T., Bene M.C., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010, 28:2529-2537.
29. Ramalho-Santos M., Yoon S., Matsuzaki Y., Mulligan R.C., Melton D.A. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002, 298:597-600.
30. Islaih M., Li B., Kadura I.A., Reid-Hubbard J.L., Deahl J.T., Altizer J.L., et al. Comparison of gene expression changes induced in mouse and human cells treated with direct-acting mutagens. Environ Mol Mutagen 2004, 44:401-419.
31. Coutts M., Cui K., Davis K.L., Keutzer J.C., Sytkowski A.J. Regulated expression and functional role of the transcription factor CHOP (GADD153) in erythroid growth and differentiation. Blood 1999, 93:3369-3378.
32. Karim H., Hashemi J., Larsson C., Moshfegh A., Fotoohi A.K., Albertioni F. The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells. Biochem Biophys Res Commun 2011, 411:156-161.
33. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
34. Maytin E.V., Habener J.F. Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. J Invest Dermatol 1998, 110:238-246.
35. Pereira R.C., Delany A.M., Canalis E. CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. Endocrinology 2004, 145:1952-1960.
36. Vladareanu A.M., Muller-Tidow C., Bumbea H., Radesi S. Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (review). Oncol Rep 2010, 23:595-604.
37. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
38. Raponi S., De Propris M.S., Intoppa S., Milani M.L., Vitale A., Elia L., et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011, 52:1098-1107.
39. Fang X., Zheng P., Tang J., Liu Y. CD24: from A to Z. Cell Mol Immunol 2010, 7:100-103.
40. Petrie K., Zelent A., Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009, 16:84-91.
41. Rhein P., Scheid S., Ratei R., Hagemeier C., Seeger K., Kirschner-Schwabe R., et al. Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemia. Leukemia 2007, 21:897-905.
42. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
43. Thai T.H., Kearney J.F. Distinct and opposite activities of human terminal deoxynucleotidyltransferase splice variants. J Immunol 2004, 173:4009-4019.
44. Chu P.G., Arber D.A. CD79: a review. Appl Immunohistochem Mol Morphol 2001, 9:97-106.
45. Taguchi T., Kiyokawa N., Mimori K., Suzuki T., Sekino T., Nakajima H., et al. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol 2003, 170:252-260.
46. Ju J.H., Jang K., Lee K.M., Kim M., Kim J., Yi J.Y., et al. CD24 enhances DNA damage-induced apoptosis by modulating NF-kappaB signaling in CD44-expressing breast cancer cells. Carcinogenesis 2011, 32:1474-1483.
47. Buss E.C., Ho A.D. Leukemia stem cells. Int J Cancer 2011, 129:2328-2336.